Guided Therapeutics (GTHP) Amortization of Deferred Charges (2018 - 2025)
Guided Therapeutics' Amortization of Deferred Charges history spans 8 years, with the latest figure at $55000.0 for Q4 2025.
- On a quarterly basis, Amortization of Deferred Charges rose 44.74% to $55000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $244000.0, a 121.82% increase, with the full-year FY2025 number at $244000.0, up 121.82% from a year prior.
- Amortization of Deferred Charges hit $55000.0 in Q4 2025 for Guided Therapeutics, up from $54000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for GTHP hit a ceiling of $172000.0 in Q2 2021 and a floor of $14000.0 in Q3 2021.
- Historically, Amortization of Deferred Charges has averaged $47350.0 across 5 years, with a median of $35000.0 in 2022.
- Biggest five-year swings in Amortization of Deferred Charges: plummeted 86.41% in 2021 and later surged 277.78% in 2025.
- Tracing GTHP's Amortization of Deferred Charges over 5 years: stood at $70000.0 in 2021, then plummeted by 54.29% to $32000.0 in 2022, then grew by 3.12% to $33000.0 in 2023, then rose by 15.15% to $38000.0 in 2024, then soared by 44.74% to $55000.0 in 2025.
- Business Quant data shows Amortization of Deferred Charges for GTHP at $55000.0 in Q4 2025, $54000.0 in Q3 2025, and $68000.0 in Q2 2025.